COSTA MESA, Calif.—Oxygen Biotherapeutics Inc. filed a Cosmetic Product Ingredient Statement (CPIS) with FDA for a series of cosmetic products developed using the company’s proprietary technology. The Dermacyte™ Gel products use Oxycyte®, a perfluorocarbon (PFC) oxygen carrier, to promote skin health and deliver cosmetic benefits. Initial launches will include Acnecyte™, an acne control product, and Wundecyte™ for wound healing. Oxygen Biotherapeutics further noted it plans to file Investigational New Drug (IND) applications for the products in the wound and acne sectors.
Oxygen Biotherapeutics Preps for Product Launches
Posted in
News,
Certifications,
Skin Care
Sources:
Comments
- Comments